IMspire150 was another phase 3, randomized open-labeled study dealing with BRAF-V600-positive melanoma patients treated with Vemurafenib and the mitogen activated protein kinase (MEK)-inhibitor Cobimitinib with and without addition of the monoclonal programmed cell death ligand 1 (PD-L1) antibody Atezolizumab [32]. The gene discussed is BRAF; the disease is melanoma.